Patent ID: 11891622
Assignee: CELL CURE NEUROSCIENCES LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. A human retinal pigment epithelium (RPE) cell population for treatment of a retinal degenerative disease comprising:
about 50,000 to about 200,000 in vitro differentiated human RPE cells,
wherein the RPE cells are in suspension,
wherein at least 95% of the human RPE cells co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), and
wherein the RPE cells have a ratio of apical secretion of pigment epithelium derived growth factor (PEDF): basal secretion of PEDF greater than 1 in a monolayer.